Skip to content

These figures do not take into account potential doses of Johnson & Johnson’s vaccine, which the FDA is expected to authorize as of this weekend. The company said it could deliver 20 million doses of its vaccine – which is given in a single injection, unlike the two-dose regimens of Moderna and Pfizer – by the end of March.

While there were reports last month that manufacturing snags could delay J & J’s first shipments, Richard Nettles, vice president of medical affairs for the company’s Janssen pharmaceutical unit, told the panel of the House that nearly four million doses would be ready to ship when the vaccine is cleared for use.

AstraZeneca and Novavax, the other vaccine makers whose executives have appeared before the House’s Energy and Commerce Oversight and Investigations Subcommittee, have yet to file a request for FDA review. – but they also store snapshots for deployment.


Source link